ArticlePloS one2021
The impact of government responses to the COVID-19 pandemic on GDP growth: Does strategy matter?
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The impact of China's non-pharmaceutical interventions on economic growth during COVID-19: a provincial-level panel analysis.BMC public health · 2026Article
- Article
- Impact of Covid-19 control strategies on health and GDP growth outcomes in 193 sovereign jurisdictions.PLOS global public health · 2025Article
- Innovative public strategies in response to COVID-19: A review of practices from China.Health care science · 2024Review
- Is SARS-CoV-2 elimination or mitigation best? Regional and disease characteristics determine the recommended strategy.Royal Society open science · 2024Article
- Fight Against the Mandatory COVID-19 Immunity Passport on Twitter: Natural Language Processing Study.Journal of medical Internet research · 2023Article
- The impact of the COVID-19 pandemic on global GDP growth.Journal of the Japanese and international economies · 2023Article
- Characteristics and outcomes of patients with severe COVID-19 in Indonesia: Lessons from the first wave.PloS one · 2023Observational
- The impact of multiple non-pharmaceutical interventions for China-bound travel on domestic COVID-19 outbreaks.Frontiers in public health · 2023Article
- Proactive vs. reactive country responses to the COVID-19 pandemic shock.PLOS global public health · 2023Article
- Non-pharmaceutical interventions and urban vehicle mobility in Seoul during the COVID-19 pandemic.Cities (London, England) · 2022Article
- The Advantages of the Zero-COVID-19 Strategy.International journal of environmental research and public health · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We analyze whether and to what extent strategies employed by governments to fight the COVID-19 pandemic made a difference for GDP growth developments in 2020. Based on the strength and speed with which governments imposed non-pharmaceutical interventions (NPIs) when confronted with waves of infections we distinguish between countries pursuing an elimination strategy and countries following a suppression / mitigation strategy. For a sample of 44 countries fixed effect panel regression results show that NPI changes conducted by elimination strategy countries had a less severe effect on GDP growth than NPI changes in suppression / mitigation strategy countries: strategy matters. However, this result is sensitive to the countries identified as "elimination countries" and to the sample composition. Moreover, we find that exogenous country characteristics drive the choice of strategy. At the same time our results show that countries successfully applying the elimination strategy achieved better health outcomes than their peers without having to accept lower growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.